Register
Visit the post for more.
Related Articles
Highlights of ASH 2024: Focus on Multiple Myeloma
According to the Surveillance, Epidemiology, and End Results Program registry, approximately 36,000 patients are annually diagnosed with multiple m…
“The End of the Golden Weather”: therapeutic strategies for mantle cell lymphoma relapsed or refractory to covalent BTK inhibitors
Mantle cell lymphoma (MCL) is a subtype of non-Hodgkin lymphoma which is often characterised by a pattern of continued relapse after frontline chemoimmunotherapy. Although patients…
Toni Choueiri: The Final Analysis of the JAVELIN Renal 101 trial – OncoDaily
Toni Choueiri: The Final Analysis of the JAVELIN Renal 101 trial / Avelumab, axitinib, cancer, ESMO Annals of Oncology, Javelin Renal 101 trial, OncoDaily,
Phenotypic clues that predict underlying cytogenetic/genetic abnormalities in myeloid malignancies: A contemporary review
This review summarises the cytomorphological and immunophenotypical alterations characteristic of myeloid neoplasms with defining genetic alterations, including the examples in the image. These cytol…
A Multimodal Biomedical Foundation Model Trained from Fifteen Million Image–Text Pairs
Biomedical data are inherently multimodal, comprising physical measurements and natural-language narratives. A generalist biomedical artificial intelligence (AI) model needs to simultaneously proce…
Breast cancer brain metastases genomic profiling identifies alterations targetable by immune-checkpoint and PARP inhibitors
npj Precision Oncology – Breast cancer brain metastases genomic profiling identifies alterations targetable by immune-checkpoint and PARP inhibitors
